Lyell Immunopharma (LYEL) News Today $0.40 -0.01 (-2.05%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.42 +0.02 (+5.58%) As of 05/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYEL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period venBio Partners LLC Makes New Investment in Lyell Immunopharma, Inc. (NASDAQ:LYEL)venBio Partners LLC acquired a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 7,102,190 shares of the company's stock, valued at approximately $4,545,000. Lyell IMay 22, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Acquires New Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)Jacobs Levy Equity Management Inc. acquired a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,385,301 shares of the company's stock, valued at approximately $887,000. JacobsMay 19, 2025 | marketbeat.comLyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025May 17, 2025 | finanznachrichten.deOrbimed Advisors LLC Decreases Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)Orbimed Advisors LLC decreased its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 49.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,103,623 shares of the company's stock after sellingMay 15, 2025 | marketbeat.comLyell Immunopharma Advances CAR T-Cell Therapy PipelineMay 14, 2025 | tipranks.comLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025May 13, 2025 | globenewswire.comForesite Capital Management V LLC Invests $5.21 Million in Lyell Immunopharma, Inc. (NASDAQ:LYEL)Foresite Capital Management V LLC acquired a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 8,133,047 shares of the company's stock, valued at approximMay 12, 2025 | marketbeat.comAlmitas Capital LLC Takes Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)Almitas Capital LLC purchased a new position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,050,520 shares of the company's stock, valued at approximately $672,000. Almitas CapitalMay 4, 2025 | marketbeat.comRenaissance Technologies LLC Purchases 1,414,746 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)Renaissance Technologies LLC lifted its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 716.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,612,146 shares of the company'May 3, 2025 | marketbeat.comLyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025May 1, 2025 | globenewswire.comLyell Immunopharma (LYEL) Projected to Post Earnings on MondayLyell Immunopharma (NASDAQ:LYEL) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-lyell-immunopharma-inc-stock/)April 30, 2025 | marketbeat.comDecheng Capital LLC Invests $7.62 Million in Lyell Immunopharma, Inc. (NASDAQ:LYEL)Decheng Capital LLC purchased a new position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,909,341 shares of the company's stock, valued at appApril 28, 2025 | marketbeat.comJohnson & Johnson Buys Shares of 823,317 Lyell Immunopharma, Inc. (NASDAQ:LYEL)Johnson & Johnson purchased a new position in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 823,317 shares of the company's stock, valued at approximately $52April 22, 2025 | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Earns Neutral Rating from HC WainwrightHC Wainwright reissued a "neutral" rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research note on Wednesday.April 18, 2025 | marketbeat.comLyell Immunopharma announces FDA granted RMAT designation to LYL314April 17, 2025 | markets.businessinsider.comLyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell LymphomaApril 15, 2025 | globenewswire.comInsider Buying: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Purchases 35,640 Shares of StockLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) Director Otis W. Brawley purchased 35,640 shares of the company's stock in a transaction dated Monday, March 31st. The shares were acquired at an average cost of $0.56 per share, for a total transaction of $19,958.40. Following the transaction, the director now owns 35,640 shares of the company's stock, valued at $19,958.40. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.April 4, 2025 | marketbeat.comOtis W. Brawley Buys 35,640 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) StockApril 3, 2025 | insidertrades.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest UpdateLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 5,980,000 shares, a decline of 26.1% from the February 28th total of 8,090,000 shares. Based on an average daily volume of 1,090,000 shares, the days-to-cover ratio is currently 5.5 days. Approximately 4.8% of the shares of the stock are sold short.March 31, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $1.05 Million Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)Charles Schwab Investment Management Inc. lifted its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 43.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,645,787 shares of the compMarch 31, 2025 | marketbeat.comBank of America Securities Keeps Their Sell Rating on Lyell Immunopharma (LYEL)March 28, 2025 | markets.businessinsider.comIs Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comTakeda Pharmaceutical Co. Ltd. Acquires Shares of 823,317 Lyell Immunopharma, Inc. (NASDAQ:LYEL)Takeda Pharmaceutical Co. Ltd. purchased a new stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 823,317 shares of the company's stock, valued at approximately $527,000. Lyell ImmunMarch 28, 2025 | marketbeat.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Director Sumant Ramachandra Purchases 200,000 SharesLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) Director Sumant Ramachandra purchased 200,000 shares of the firm's stock in a transaction on Friday, March 21st. The stock was acquired at an average price of $0.58 per share, with a total value of $116,000.00. Following the completion of the transaction, the director now owns 200,000 shares in the company, valued at approximately $116,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.March 26, 2025 | marketbeat.comFavourable Signals For Lyell Immunopharma: Numerous Insiders Acquired StockMarch 20, 2025 | finance.yahoo.comInsider Buying: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Buys 158,000 Shares of StockLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) Director Richard Klausner bought 158,000 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were bought at an average price of $0.60 per share, with a total value of $94,800.00. Following the transaction, the director now owns 843,365 shares of the company's stock, valued at $506,019. The trade was a 23.05 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.March 19, 2025 | marketbeat.comCharles W. Newton Acquires 200,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) StockLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) CFO Charles W. Newton bought 200,000 shares of the company's stock in a transaction on Monday, March 17th. The shares were acquired at an average price of $0.56 per share, with a total value of $112,000.00. Following the transaction, the chief financial officer now directly owns 200,000 shares in the company, valued at approximately $112,000. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.March 19, 2025 | marketbeat.comLynn Seely Buys 175,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) StockLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) CEO Lynn Seely purchased 175,000 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was purchased at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the purchase, the chief executive officer now owns 712,500 shares in the company, valued at $434,625. This represents a 32.56 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.March 19, 2025 | marketbeat.comShort Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Declines By 16.2%Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 8,090,000 shares, a drop of 16.2% from the February 13th total of 9,650,000 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is currently 7.0 days. Currently, 6.5% of the shares of the stock are short sold.March 19, 2025 | marketbeat.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Director Richard Klausner Purchases 158,000 SharesMarch 19, 2025 | insidertrades.comHC Wainwright Has Optimistic Outlook of LYEL Q1 EarningsLyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) - Research analysts at HC Wainwright increased their Q1 2025 EPS estimates for Lyell Immunopharma in a report issued on Thursday, March 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.17) per share for the qMarch 17, 2025 | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Receives Neutral Rating from HC WainwrightHC Wainwright restated a "neutral" rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Thursday.March 14, 2025 | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Issues Quarterly Earnings ResultsLyell Immunopharma (NASDAQ:LYEL - Get Free Report) released its earnings results on Tuesday. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%.March 12, 2025 | marketbeat.comLyell Immunopharma reports Q4 net loss $45.9M vs. net loss $44M last yearMarch 12, 2025 | markets.businessinsider.comLyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024March 11, 2025 | globenewswire.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Down 16.3% in FebruaryLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the recipient of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 9,650,000 shares, a drop of 16.3% from the January 31st total of 11,530,000 shares. Approximately 7.7% of the company's shares are sold short. Based on an average trading volume of 1,270,000 shares, the short-interest ratio is presently 7.6 days.March 6, 2025 | marketbeat.comLyell Immunopharma (LYEL) to Release Earnings on WednesdayLyell Immunopharma (NASDAQ:LYEL) will be releasing earnings on Wednesday, February 26.February 19, 2025 | marketbeat.comLyell Immunopharma Announces Participation in Upcoming Investor ConferencesFebruary 18, 2025 | globenewswire.comLyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stakeJanuary 31, 2025 | finance.yahoo.comLyell Immunopharma Faces Nasdaq delisting over share priceJanuary 25, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Lyell Immunopharma (LYEL) and Gilead Sciences (GILD)January 16, 2025 | markets.businessinsider.comLyell Immunopharma price target lowered to 60c from $1 at BofAJanuary 12, 2025 | markets.businessinsider.comLyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare ConferenceJanuary 9, 2025 | globenewswire.comBank of America Securities Sticks to Its Sell Rating for Lyell Immunopharma (LYEL)January 7, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)December 24, 2024 | markets.businessinsider.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Shares Sold by Fmr LLCFmr LLC cut its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 62.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,024,583 shares of the company's stock after selling 1,708,879 shares during the quaDecember 16, 2024 | marketbeat.comLyell Immunopharma Inc Ordinary SharesDecember 12, 2024 | morningstar.comLyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual MeetingDecember 9, 2024 | globenewswire.comMitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market ChallengesNovember 13, 2024 | markets.businessinsider.comThe Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 ExpertsNovember 12, 2024 | benzinga.com Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Email Address LYEL Media Mentions By Week LYEL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LYEL News Sentiment▼0.840.87▲Average Medical News Sentiment LYEL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LYEL Articles This Week▼21▲LYEL Articles Average Week Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ZVRA News UPB News AMLX News ARVN News DNA News ALT News SAGE News CGEM News SEPN News TECX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LYEL) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LYEL Stock Free LYEL Stock Alerts